ruxolitinib treatment in a patient with primary myelofibrosis resistant to conventional therapies and splenectomy: a case report
Clicks: 288
ID: 128902
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
288 views
33 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #11 of 54 articles by views in proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.
| Reference Key |
ayl2015turkishruxolitinib
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Meltem Aylı;Muhit Özcan;Güldane Cengiz Seval |
| Journal | proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017 |
| Year | 2015 |
| DOI |
10.4274/tjh.2013.0338
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.